[Isolated liver perfusion with melphalan followed by pembrolizumab therapy for unresectable metastases of uveal melanoma to the liver].
Andrey D KaprinSergey A IvanovUnguryan Vladimir MikhailovichAnton Nikolaevich KazantsevBelov Yuri VladimirovichPublished in: Khirurgiia (2023)
Uveal melanoma accounts for 80% of all ocular melanomas, and 30-60% of patients have metastases to the liver. A few patients are candidates for liver resection, and this disease is associated with poor prognosis. There are few data on optimal management of metastatic uveal melanoma. Isolated hepatic perfusion is a perspective method for regional treatment of inoperable metastatic liver lesions with uveal melanoma. We present a patient with uveal melanoma who underwent previous enucleation of the eye. Cancer progressed 15 years later as an isolated inoperable metastatic liver lesion. The patient underwent isolated liver perfusion with melphalan, hyperthermia and oxygenation. Subsequently, the patient received systemic therapy with pembrolizumab. Partial response was achieved 1 month after the procedure. There was no progression for 20 months after surgery under systemic therapy with pembrolizumab. Thus, isolated liver chemoperfusion with melphalan is advisable in these patients.
Keyphrases
- end stage renal disease
- poor prognosis
- ejection fraction
- newly diagnosed
- small cell lung cancer
- squamous cell carcinoma
- chronic kidney disease
- high dose
- case report
- peritoneal dialysis
- long non coding rna
- advanced non small cell lung cancer
- machine learning
- big data
- deep learning
- minimally invasive
- mesenchymal stem cells
- smoking cessation
- tyrosine kinase
- epidermal growth factor receptor
- bone marrow
- optical coherence tomography
- drug induced